跳至主要内容
临床试验/NCT05773001
NCT05773001招募中1 期

Macrophage Regulation of Ozone-Induced Lung Inflammation

Robert Tighe, MD2 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2023年5月18日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
招募中
发起方
入组人数
100
试验地点
2
主要终点
Change in the abundance of monocyte-derived alveolar macrophages

研究概览

简要总结

The purpose of this research study to understand how prior respiratory infections affect the susceptibility to lung inflammation following environmental exposures.

详细描述

Study participants will undergo a 1-day screening that includes a blood draw and breathing testing, return for a two-day series of testing to include blood draw, and brief breathing test before and after an inhaled challenge with either filtered air (FA) or ozone (O3). Participants return the next day for a brief breathing test, a blood draw and a procedure called bronchoscopy to evaluate the lung after the challenge.

Participants then return 18 - 20 days later to repeat the two-day series of testing to be challenged with the exposure not received on the first series, (FA or O3). Each visit will take about 3 - 3.5 hours. Follow-up phone calls from the study team will occur at 24 hours after each 2-day test series.

Total study duration is about one to one-and a half months.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Crossover
主要目的
Other
盲法
Single (Participant)

入排标准

年龄范围
18 Years 至 55 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Individuals between 18-55 yrs. of age (No subject will be excluded from the study on the basis of gender or ethnicity)
  • Individuals with knowledge of prior respiratory viral infection history allowing them to be segregated into one of three cohorts
  • Cohort 1 - No history of respiratory viral infection (defined as no symptoms consistent with respiratory viral infection nor history of a positive respiratory viral test)
  • Cohort 2 - Documented mild respiratory viral infection (a positive test, either PCR- or antigen-based) but with mild to no symptoms and no evidence of a lower respiratory tract infection (including no hospitalization, and no oxygen use)
  • Cohort 3 - History of respiratory viral infection and symptoms/imaging consistent with a lower respiratory tract infection who have recovered, are >6 months out from their infection, and have normal lung function (spirometry with FVC, FEV1 and FEV1/FVC)
  • There will be no maximal period from respiratory viral infection for inclusion in the study, the minimal period will be >6 months out from infection

排除标准

  • Individuals with prior respiratory viral pneumonia who have ongoing respiratory symptoms, are still using supplemental oxygen, or have abnormal lung function
  • Current smokers of tobacco products including e-cigarettes or those with previous smoking history within the prior 5 years
  • Pregnant women and women who are presently lactating.
  • Subjects that have received antibiotic administration or an upper respiratory infection within the previous 4 weeks
  • College and graduate students or employees who are under direct supervision by any of the investigators in this protocol
  • Alcohol or illicit substance abuse
  • Chronic cardio/pulmonary respiratory disorders or other medical conditions as determined by the investigator
  • Increased airway hyperresponsiveness at baseline as measured by a positive methacholine challenge response (methacholine PC20 FEV1 < 4 mg/ml)
  • Subjects will be requested to refrain from antihistamines, nonsteroidal anti-inflammatory agents, antioxidants (e.g. beta-carotene, selenium, and lutein) and supplemental vitamins (e.g. C and E), for 1 week prior to, and during testing.

研究组 & 干预措施

Cohort 2

Other

Documented mild respiratory viral infection

干预措施: Ozone (Drug)

Cohort 1

Other

no history of respiratory viral infection

干预措施: Ozone (Drug)

Cohort 3

Other

Respiratory viral pneumonia

干预措施: Ozone (Drug)

结局指标

主要结局

Change in the abundance of monocyte-derived alveolar macrophages

时间窗: Baseline, Day 18-20

Change in the abundance of monocyte-derived alveolar macrophages and association to measures of O3-induced inflammation (BAL cell neutrophils, albumin and cytokine production)

Change in the abundance of monocyte-derived alveolar macrophages

时间窗: Baseline, Day 18-20

\- Change in the abundance of monocyte-derived alveolar macrophages and association to measures of O3-induced inflammation (BAL cell neutrophils, albumin and cytokine production)

次要结局

  • Change in the abundance of autonomous CSF-1 expression in alveolar macrophages(Baseline, Day 18-20)
  • Association between prior evidence of respiratory viral pneumonia(Baseline, Day 18-20)
  • Association between prior evidence of respiratory viral infection without pneumonia(Baseline, Day 18-20)
  • Change in the abundance of autonomous CSF-1 expression in alveolar macrophages(Baseline, Day 18-20)
  • Association between prior evidence of COVID pneumonia(Baseline, Day 18-20)
  • Association between prior evidence of COVID infection without pneumonia(Baseline, Day 18-20)

研究者

发起方
Robert Tighe, MD
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Robert Tighe, MD

Associate Professor of Medicine

Duke University

研究点 (2)

Loading locations...

相似试验

Macrophage Regulation of Ozone-Induced Lung... | 临床试验